CRISPR Therapeutics is a pioneering biotechnology company that has evolved from a research-stage entity into a leader in gene editing, with a diverse portfolio of product candidates targeting various disease areas such as hemoglobinopathies, oncology, regenerative medicine, cardiovascular diseases, and rare diseases. Leveraging Nobel Prize-winning CRISPR technology, the company aims to develop transformative medicines that can significantly impact patient care. Headquartered in Zug, Switzerland, CRISPR Therapeutics operates a wholly-owned U.S. subsidiary and has R&D facilities in Boston and San Francisco, along with business offices in London. The company is committed to fostering an inclusive workplace and adheres to equal employment opportunity principles.